Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke‐Pearson, D. L., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,034
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,437
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B. T., & Mills, G. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2644 · Cited by 1,372
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“BRCA1 promoter hypermethylation has been reported in approximately 10% to 20% of HGSOCs and is mutually exclusive of BRCA1/2 mutations, suggesting that there is strong selective pressure to inactivate BRCA via either mutation or epigenetic silencing in this disease (16, 27, 28).”
Background
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. L. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,196
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Gelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,130
Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
Polo, S. E., & Jackson, S. P. (2011) · Genes & Development · doi:10.1101/gad.2021311 · Cited by 1,092
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings
McVey, M., & Lee, S. E. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.007 · Cited by 1,039
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,022
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 975
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 960
Cancer of the ovary.
Cannistra, S. (1993) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 957
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J., Amunugama, R., Hajdú, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 945
Self-citation
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 915
XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage
Masson, M., Niedergang, C., Schreiber, V., Muller, S., Murcia, J. M., & de MURCIA, G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3563 · Cited by 910
A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
Escribano‐Diaz, C., Orthwein, A., Fradet‐Turcotte, A., Xing, M., Young, J. T. F., Tkáč, J., Cook, M. A., Rosebrock, A. P., Munro, M., Canny, M. D., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.001 · Cited by 903
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., & Iliakis, G. E. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl840 · Cited by 892
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Winter, W. E., Maxwell, G. L., Tian, C., Carlson, J. W., Ozols, R. F., Rose, P. G., Markman, M. M., Armstrong, D. K., Muggia, F. M., & McGuire, W. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2517 · Cited by 844
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith‐McCune, K., Broaddus, R. R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 817
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Mateos‐Gómez, P. A., Gong, F., Nair, N., Miller, K. M., Denchi, E. L., & Sfeir, A. J. (2015) · Nature · doi:10.1038/nature14157 · Cited by 801
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
Pfisterer, J., Plante, M., Vergote, I. B., du Bois, A., Hirte, H. W., Lacave, Á. J., Wagner, U. A. G., Staehle, A., Stuart, G. C. E., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 752
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H., et al. (2010) · Nature Genetics · doi:10.1038/ng.569 · Cited by 743
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 711
Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining
Audebert, M., Salles, B., & Calsou, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404524200 · Cited by 709
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J. V., ARANGO, H. A., LaPolla, J. P., Hoffman, M. S., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 690
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Popova, T. G., Manié, É., Rieunier, G., Caux‐Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal‐Zafrani, B., Bollet, M. A., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 683
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 676
RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
Chapman, J. R., Barral, P., Vannier, J., Borel, V., Steger, M., Tomás‐Loba, A., Sartori, A. A., Adams, I. R., Batista, F. D., & Boulton, S. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.002 · Cited by 663
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 656
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y. H., & Yu, A. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 653
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 642
53BP1 Regulates DSB Repair Using Rif1 to Control 5′ End Resection
Zimmermann, M., Lottersberger, F., Buonomo, S. B. C., Sfeir, A. J., & de Lange, T. (2013) · Science · doi:10.1126/science.1231573 · Cited by 628
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres‐Lockhart, K., Prat, A., Antón, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 616
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrík, M., Bouwman, P., Bártková, J., Gogola, E., Warmerdam, D. O., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 611
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Norquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 593
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Liu, J. F., Barry, W. T., Birrer, M. J., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B. J., Buss, M. K., Nattam, S. R., Hurteau, J. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 592
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
Boyd, J., Sonoda, Y., Federici, M. G., Bogomolniy, F., Rhei, E., Maresco, D., Saigo, P., Almadrones, L., Barakat, R., Brown, C., et al. (2000) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.283.17.2260 · Cited by 570
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 568
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G. R., Kalmyrzaev, B., Warren-Perry, M., Snape, K. M. G., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 547
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 546
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A. J., Boon, U., Sol, W., van Deemter, L., Zander, S. A. L., Drost, R., Wientjens, E., Ji, J. J., Aly, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 532
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B. S., DeFelice, M. T., Pochanard, P., Ducar, M. D., Hummelen, P. V., MacConaill, L. E., Hahn, W. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0184 · Cited by 529
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Vos, M. D., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 522
Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., Mazoyer, S., Chenevix-Trench, G., Easton, D. F., Antoniou, A. C., et al. (2015) · JAMA · doi:10.1001/jama.2014.5985 · Cited by 521
DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss, J. L., & Wang, J. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.20.7501 · Cited by 503
Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double‐strand break repair and serves as a barrier to error‐prone DNA repair pathways.
Boulton, S. J., & Jackson, S. P. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00890.x · Cited by 502
Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage
Deriano, L., & Roth, D. B. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155540 · Cited by 496
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N. J., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 486
Self-citation
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 468
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 467
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N. D., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 459
Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial
Markman, M. M., Liu, P., Wilczynski, S. P., Monk, B. J., Copeland, L. J., Alvarez, R. D., Jiang, C. S., & Alberts, D. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
Gagné, J., Isabelle, M., Lo, K. S., Bourassa, S., Hendzel, M. J., Dawson, V. L., Dawson, T. M., & Poirier, G. G. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn771 · Cited by 443
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Moskwa, P., Buffa, F. M., Pan, Y., Panchakshari, R. A., Gottipati, P., Muschel, R. J., Beech, J. S., Kulshrestha, R., Abdelmohsen, K., Weinstock, D. M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.005 · Cited by 436
Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins
Ahel, I., Ahel, D., Matsusaka, T., Clark, A. J., Pines, J., Boulton, S. J., & West, S. C. (2008) · Nature · doi:10.1038/nature06420 · Cited by 429
Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
Virgilio, M. D., Callén, E., Yamane, A., Zhang, W., Janković, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., et al. (2013) · Science · doi:10.1126/science.1230624 · Cited by 423
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes‐Davies, L., Huntsman, D. D., Ruas, M., Fuks, F., Bye, J. M., Chin, S., Milner, J., Brown, L. A., Hsu, F. D., Gilks, C. B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 422
Unrepaired DNA Breaks in p53-Deficient Cells Lead to Oncogenic Gene Amplification Subsequent to Translocations
Zhu, C., Mills, K. D., Ferguson, D. O., Lee, C., Manis, J., Fleming, J., Gao, Y., Morton, C. C., & Alt, F. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00770-5 · Cited by 421 · cited 1×
“Early evidence for alt-EJ came from studies in yeast and mammalian cells deficient in C-NHEJ that were still able to repair DSBs via end joining (113, 114) and by the observation that mice deficient in C-NHEJ still exhibited chromosomal translocations and V(D)J recombination (115, 116).”
Background
Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Timms, K. M., Abkevich, V., Hughes, E., Neff, C. D., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 418
Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
D’Andrea, A. D. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809889 · Cited by 390
Self-citation
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Hennessy, B. T., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 376
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 360
53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
Callén, E., Virgilio, M. D., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H. T., Faryabi, R. B., Polato, F., Santos, M. A., Starnes, L. M., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.023 · Cited by 356
Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ
Kent, T., Chandramouly, G., McDevitt, S., Ozdemir, A. Y., & Pomerantz, R. T. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2961 · Cited by 355
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S. K., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 345
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Li, M., & Yu, X. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.025 · Cited by 340
Rag mutations reveal robust alternative end joining
Corneo, B., Wendland, R. L., Deriano, L., Cui, X., Klein, I. A., Wong, S.-Y., Arnal, S. M., Holub, A. J., Weller, G. R., Pancake, B. A., et al. (2007) · Nature · doi:10.1038/nature06168 · Cited by 340
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 336
DNA Ligase III as a Candidate Component of Backup Pathways of Nonhomologous End Joining
Wang, H., Rosidi, B., Perrault, A. R., Wang, M., Zhang, L., Windhofer, F., & Iliakis, G. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3055 · Cited by 334
Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma
Sakai, W., Swisher, E. M., Jacquemont, C. F., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 329
Involvement of poly(ADP-ribose) polymerase in base excision repair
Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., de la Rubia, G., Oliver, J., Rolli, V., Murcia, J. M., & de MURCIA, G. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80040-6 · Cited by 327
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4–ligase IV during chromosomal translocation formation
Simsek, D., & Jasin, M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1773 · Cited by 321
MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
Boersma, V., Moatti, N., Segura‐Bayona, S., Peuscher, M. H., van der Torre, J., Wevers, B. A., Orthwein, A., Durocher, D., & Jacobs, J. J. L. (2015) · Nature · doi:10.1038/nature14216 · Cited by 311
Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors
Shafee, N., Smith, C. R., Wei, S., Kim, Y. H., Mills, G. B., Hortobágyi, G. N., Stanbridge, E. J., & Lee, E. Y.-H. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5480 · Cited by 308
Classical and Alternative End-Joining Pathways for Repair of Lymphocyte-Specific and General DNA Double-Strand Breaks
Boboilă, C., Alt, F. W., & Schwer, B. (2012) · Advances in immunology · doi:10.1016/b978-0-12-394300-2.00001-6 · Cited by 306
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
Rottenberg, S., Nygren, A. O. H., Pajic, M., van Leeuwen, F. W. B., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G. A., van Tellingen, O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702955104 · Cited by 306
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Murai, J., Zhang, Y., Morris, J., Ji, J. J., Takeda, S., Doroshow, J. H., & Pommier, Y. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 300
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 293
Self-citation
ATR: a master conductor of cellular responses to DNA replication stress
Flynn, R. L., & Zou, L. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.005 · Cited by 290
Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells
Hochegger, H., Dejsuphong, D., Fukushima, T., Morrison, C. G., Sonoda, E., Schreiber, V., Zhao, G., Saberi, A., Masutani, M., Adachi, N., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601015 · Cited by 290
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D’Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 290
Self-citation
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 290
An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway
Zhang, Y., & Jasin, M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1940 · Cited by 287
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomský, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 271
Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.
Doroshow, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4514 · Cited by 268
RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair
Feng, L., Fong, K.-W., Wang, J., Wang, W., & Chen, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.457440 · Cited by 267
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 267
Self-citation
BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance
Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C. N., van der Heijden, I., van der Gulden, H. M. L., Wientjens, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.014 · Cited by 266
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 264
Biochemical evidence for Ku-independent backup pathways of NHEJ
Wang, H. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg728 · Cited by 260
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells
Fattah, F. J., Lee, E. H., Weisensel, N. A., Wang, Y., Lichter, N., & Hendrickson, E. A. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000855 · Cited by 244
Double-strand break repair in Ku86- and XRCC4-deficient cells
Kabotyanski, E. B., Gomelsky, L., Han, J.-O., Roth, D. B., & Stamato, T. D. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.23.5333 · Cited by 244
Synthetic Lethality — A New Direction in Cancer-Drug Development
Iglehart, J. D., & Silver, D. P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0903044 · Cited by 234
Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer
Bolton, K., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S., Karlan, B., Lambrechts, D., Despierre, E., Barrowdale, D., McGuffog, L., et al. (2012) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2012.20 · Cited by 219
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & Bono, J. S. D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 218
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Langelier, M.-F., & Pascal, J. M. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.01.003 · Cited by 215
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 201
How do real tumors become resistant to cisplatin?
Borst, P., Rottenberg, S., & Jonkers, J. (2008) · Cell Cycle · doi:10.4161/cc.7.10.5930 · Cited by 192
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L. M., Zujewski, J. A., Yu, M., Gordon, N., Ji, J. J., Sissung, T. M., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 185
Fanconi anemia pathway–deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated
Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., la Vega, M. A. D., Moreau, L. A., Shimamura, A., & D’Andrea, A. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31245 · Cited by 178
Self-citation
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
Pettitt, S. J., Rehman, F. L., Bajrami, I., Brough, R., Wållberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061520 · Cited by 178
Targeting the S and G2 checkpoint to treat cancer
Chen, T., Stephens, P., Middleton, F. K., & Curtin, N. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.009 · Cited by 176
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
Oplustilova, L., Wolanin, K., Mistrík, M., Kořínková, G., Šimková, D., Bouchal, J., Lenobel, R., Bártková, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 167
A DNA Repair Pathway–Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167
Self-citation
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 166
Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress
Gagné, J., Pic, É., Isabelle, M., Krietsch, J., Éthier, C., Paquet, É. R., Kelly, I., Boutin, M., Moon, K., Foster, L. J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks486 · Cited by 165
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M. E., Kummar, S., Szabo, E. M., Yancey, M. A., Ji, J. J., Mannargudi, B. M., Woo, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2425 · Cited by 164
Amplification of 11q13 in ovarian carcinoma
Brown, L. A., Kalloger, S. E., Miller, M. A., Shih, I., McKinney, S. E., Santos, J. L., Swenerton, K., Spellman, P. T., Gray, J. W., Gilks, C. B., et al. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20549 · Cited by 160
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4Preprint
Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015) · Genes & Development · doi:10.1101/gad.256214.114 · Cited by 157
Self-citation
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
PARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 147
Self-citation
The membrane attack complex of complement induces caspase activation and apoptosis
Nauta, A. J., Daha, M. R., Tijsma, O., van de Water, B., Tedesco, F., & Roos, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3 · Cited by 147
Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y. G., & Murai, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0551 · Cited by 142
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 140
A High-Throughput Functional Complementation Assay for Classification of BRCA1 Missense Variants
Bouwman, P., van der Gulden, H., van der Heijden, I., Drost, R., Klijn, C. N., Prasetyanti, P., Pieterse, M., Wientjens, E., Seibler, J., Hogervorst, F. B. L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0094 · Cited by 140
The Role of Mechanistic Factors in Promoting Chromosomal Translocations Found in Lymphoid and Other Cancers
Zhang, Y., Gostissa, M., Hildebrand, D. G., Becker, M. S., Boboilă, C., Chiarle, R., Lewis, S. M., & Alt, F. W. (2010) · Advances in immunology · doi:10.1016/s0065-2776(10)06004-9 · Cited by 135
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Ceccaldi, R., O’Connor, K. W., Mouw, K. W., Li, A. Y., Matulonis, U. A., D’Andrea, A. D., & Konstantinopoulos, P. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2593 · Cited by 133
Self-citation
VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
Lim, J. Y., Yang, K. Y., Taylor‐Harding, B., Wiedemeyer, W. R., & Buckanovich, R. J. (2014) · Neoplasia · doi:10.1016/j.neo.2014.04.003 · Cited by 131
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 116
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J. L., Wass, E., & Khabele, D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.007 · Cited by 115
Self-citation
Targeting homologous recombination repair defects in cancer
Evers, B., Helleday, T., & Jonkers, J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.001 · Cited by 115
CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D’Andrea, A. D. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-24 · Cited by 115
Self-citation
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Patel, A. G., Flatten, K. S., Schneider, P. A., Dai, N. T., McDonald, J. S., Poirier, G. G., & Kaufmann, S. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296475 · Cited by 111
DNA polymerase POLQ and cellular defense against DNA damage
Yousefzadeh, M. J., & Wood, R. D. (2012) · DNA repair · doi:10.1016/j.dnarep.2012.10.004 · Cited by 109
BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark
Søgaard, M., Kjær, S. K., Cox, M. J., Woźniak, E. L., Høgdall, E. V. S., Høgdall, C. K., Blaakær, J., Jacobs, I. J., Gayther, S. A., & Ramus, S. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4806 · Cited by 105
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
Ruscito, I., Dimitrova, D., Vasconcelos, I. I. M., Gellhaus, K., Schwachula, T., Bellati, F., Zeillinger, R., Benedetti-Panici, P., Vergote, I. B., Mahner, S., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.05.001 · Cited by 103
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
Safra, T., Borgato, L., Nicoletto, M. O., Rolnitzky, L. M., Pelles-Avraham, S., Geva, R., Donach, M. E., Curtin, J. P., Novetsky, A. P., Grenader, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0272 · Cited by 94
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 93
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88
Role of gemcitabine in ovarian cancer treatment
Lorusso, D., Stefano, A. D., Fanfani, F., & Scambia, G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj979 · Cited by 81
MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability
Choi, Y. E., Pan, Y., Park, E., Konstantinopoulos, P. A., De, S., D’Andrea, A. D., & Chowdhury, D. (2014) · eLife · doi:10.7554/elife.02445 · Cited by 79
Self-citation
cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.
Thigpen, T., Shingleton, H. M., Homesley, H. D., Lagasse, L. D., & Blessing, J. A. (1979) · PubMed · Cited by 74
Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair
Paddock, M. N., Bauman, A. T., Higdon, R., Kolker, E., Takeda, S., & Scharenberg, A. M. (2011) · DNA repair · doi:10.1016/j.dnarep.2010.12.005 · Cited by 68
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
Rossof, A. H., Rw, T., Stephens, R., Thigpen, T., Mk, S., Groppe, C. W., Hj, E., & Fisher, R. I. (1979) · PubMed · Cited by 68
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
Choi, Y. E., Battelli, C., Watson, J., Liu, J. F., Curtis, J. D., Morse, A., Matulonis, U. A., Chowdhury, D., & Konstantinopoulos, P. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1929 · Cited by 60
Self-citation
The current treatment of recurrent ovarian cancer
Herzog, T. J. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0074-9 · Cited by 60
Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase
Li, X., Delzer, J., Voorman, R. L., de Morais, S. M., & Lao, Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037820 · Cited by 60
Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer
Pulsipher, M. A., Kupfer, G. M., Näf, D., Suliman, A., Lee, J.-S., Jakobs, P. M., Grompe, M., Joenje, H., Sieff, C. A., Guinan, E. C., et al. (1998) · Molecular Medicine · doi:10.1007/bf03401752 · Cited by 59
Self-citation
BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer
Tammaro, C., Raponi, M., Wilson, D. I., & Baralle, D. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120140 · Cited by 56
Intraperitoneal Chemotherapy Comes of Age
Cannistra, S. A. (2006) · New England Journal of Medicine · doi:10.1056/nejme058308 · Cited by 56
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study
Weberpals, J. I., Tu, D., Squire, J. A., Amin, M. S., Islam, S., Pelletier, L. B., O'Brien, A. M., Hoskins, P. J., & Eisenhauer, E. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq770 · Cited by 49
Treating Cancer by Targeting a Weakness
Brody, L. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr052331 · Cited by 43
Oral Etoposide for the Treatment of Recurrent Ovarian Cancer
Ozols, R. F. (1999) · Drugs · doi:10.2165/00003495-199958003-00007 · Cited by 20
Ovarian Cancer: Is Dose Intensity Dead?
Ozols, R. F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1723 · Cited by 14
Management of Ovarian Cancer
Awtrey, C. S. (2012) · JAMA · doi:10.1001/jama.2012.269 · Cited by 13
Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.
Strickland, K. C., Howitt, B. E., Rodig, S. J., Ritterhouse, L. L., D’Andrea, A. D., Matulonis, U. A., & Konstantinopoulos, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5512 · Cited by 12
Self-citation
215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib
Swisher, E., Brenton, J. D., Kaufmann, S., Oza, A. M., Coleman, R. L., O’Malley, D. M., Konecny, G. E., Ma, L., Harrell, M. I., Visscher, D. W., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70341-7 · Cited by 10
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.
Do, K. T., Wilsker, D. F., Balasubramanian, P., Zlott, J., Jeong, W., Lawrence, S. M., Kinders, R. J., Collins, J. M., Chen, A. P., Doroshow, J. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2503 · Cited by 7
Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.
Johnson, S. F., Johnson, N., Chi, D., Primack, B., D’Andrea, A. D., Lim, E., & Shapiro, G. I. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1788 · Cited by 4
Self-citation

Sorted by citations

ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M. L., Okamoto, A., Moore, K. N., Ben-Baruch, N. E., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 915
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
“Numerous mechanisms of acquired resistance to PARPi have been described in pre-clinical and clinical studies [65, 66]; these can be grouped into three main classes (Figure 2).”
Background
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O’Carrigan, B., Jackson, S. P., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 642
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S. J., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 630
Self-citation

See all 946

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks